Importantly, the difference in tumor growth between the Ctrl and Stk24 KO groups disappeared after anti‐CD8α mAb treatment (Figure 3F), indicating that STK24 supports CT26 tumor development through inhibition of CD8+T cell‐dependent cytotoxic T cell responses. The gene discussed is CD8A; the disease is neoplasm.